Neutron capture therapy with gadopentetate dimeglumine: Experiments on tumor-bearing rats

Khokhlov, V.F.; Yashkin, P.N.; Silin, Dimitry I.; Djorova, E. S.; Lawaczeck, Rüdiger

doi:10.1016/s1076-6332(05)80341-1

Cited by 18 publications

(9 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…32 The latter case is probably due to the background capture of thermal neutrons by body elements such as 1 H (0.333 barns), 12 C (0.0035 barns), 14 N (1.83 barns), 16 O (0.00019 barns), 31 P (0.18 barns), and 35 Cl (32.68 barns), 29 as observed by others. 28,29,31,32 This indicates that low thermal neutron beam irradiation doses should be used to avoid cell damage by thermal neutrons on their own. It should be noted that the Gd+/n+ mice group exhibited a cancer volume decrease (i.e., V/V 0 < 1.0) for 16 days aer the thermal neutron beam irradiation with a minimum of V/V 0 ¼ 0.3 at day 5.…”

Section: View Article Onlinementioning

confidence: 99%

“…23,24 Nevertheless, the GdNCT suffers from the lack of suitable Gdchemicals, whereas two clinically applicable B-chemicals are available for BNCT. 25 Until now, only the commercial Gd-chelates and nanocomposites containing them have been applied to the in vivo GdNCT of cancer using cancer model mice 23,24,[26][27][28][29][30][31][32] and dogs. 33 However, they have shown limitations because commercial Gd-chelates are extracellular 1,2 and not specic to cancer, 1,2 and the nanocomposites are generally too big to be IV administered.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

In vivo neutron capture therapy of cancer using ultrasmall gadolinium oxide nanoparticles with cancer-targeting ability

Choi

Yue

et al. 2020

RSC Adv.

View full text Add to dashboard Cite

show abstract

Section: View Article Onlinementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

In vivo neutron capture therapy of cancer using ultrasmall gadolinium oxide nanoparticles with cancer-targeting ability

Choi

Yue

et al. 2020

RSC Adv.

View full text Add to dashboard Cite

show abstract

“…Growth of Gadolinium-infused tumors was significantly inhibited compared to that of control tumors between the 16 th and 23 rd days after treatment. In vivo Gd-DTPA therapeutic effect in rats with Jensen sarcomas was also reported [30]. Gd-DTPA was administered directly into the tumor prior to neutron irradiation.…”

Section: Small Sized Gd Chelates For Gd-nctmentioning

confidence: 86%

Insights into the Use of Gadolinium and Gadolinium/Boron-Based Agents in Imaging-Guided Neutron Capture Therapy Applications

et al. 2016

View full text Add to dashboard Cite

Gadolinium neutron capture therapy (Gd-NCT) is currently under development as an alternative approach for cancer therapy. All of the clinical experience to date with NCT is done with 10 B, known as BNCT, a binary treatment combining neutron irradiation with the delivery of boron-containing compounds to tumors. Currently, the use of gadolinium for NCT has been getting more attention because of its highest neutron cross-section. Although Gd-NCT was first proposed many years ago, its development has suffered due to lack of appropriate tumor-selective Gd-agents. This review aims to highlight the recent advances for the design, synthesis and biological testing of new Gd-and B-Gd-containing compounds with the task of finding the best systems able to improve the NCT clinical outcome. Keywords:Gadolinium Neutron Capture Therapy, Boron Neutron Capture Therapy, MRI, Gd contrast agents, Tumor Treatment, Nanosized Gd agents. 3 General introduction on NCT: rationale and applicationNeutron Capture Therapy (NCT) is a non-conventional radiotherapy that combines low energy neutron irradiation with the presence of a neutron-absorbing substance at the targeted cells [1][2].Two isotopes are of major interest because of their large capture cross section: head and neck recurrent cancer [6][7], melanoma [8] and adenocarcinoma liver metastases [9]; ii) sodium mercaptoundecahydro-closo-dodecaborate (BSH) that has been investigated for the treatment of malignant glioma [10]. Despite their clinical use and the safe and effective BNCT, trials performed with these two drugs until now, both BPA and BSH show low selectivity and great efforts have been made by several research groups to develop new and more selective boron delivery agents [11][12].The use of BNCT to destroy malignant cells was proposed long time ago [13]. In spite of huge promises, it has not attained an established position in the mainstream medicine.However, the methodology has never been discarded and it remains in an intermediate state with a small group of enthusiast supporters and many critical spectators. The reasons why BNCT has not maintained the original promises rely mainly in the lack of properly designed agents. The conditions for an effective therapeutic output are well established: the BNCT agent must reach selectively a given concentration inside cells and the not-attainment of this task makes the therapy less effective. Only a proper NCT agent design (based on an improved knowledge on how molecules enter healthy and diseased cells) allows to reach selectively the needed threshold of intracellular concentration required to drive the breakthrough of BNCT in the field of conventional and diffused treatments for cancer. Moreover, the in vivo assessment of the amount of NCT agent can now be tackled by its conjugation to a suitable imaging-reporter. [14][15] To date there is no non-invasive means to evaluate boron concentration in tumor and healthy tissues of the subject undergoing the irradiation. Thus, dose calculations are based on boron content values in...

show abstract

“…T/N比很高(~10) [13] . Khokhlov等人 [14] 报道了以Gd-DTPA为携带剂, 通过NCT治疗大鼠Jensen肉瘤的工作. 瘤内注射13.75 mg/g肿瘤组织的钆, 随后用注量率为认为, 肿瘤细胞的细胞核Gd摄取量不足决定了以Gd-DTPA和Gd-DOTA为Gd 携带剂无法取得较好的治疗效果.…”

Section: 对于钆中子俘获治疗肿瘤组织中unclassified

Gadolinium delivery agents for neutron capture therapy

Zhang

Wang

2021

Chin. Sci. Bull.

View full text Add to dashboard Cite

Neutron capture therapy with gadopentetate dimeglumine: Experiments on tumor-bearing rats

Cited by 18 publications

References 10 publications

In vivo neutron capture therapy of cancer using ultrasmall gadolinium oxide nanoparticles with cancer-targeting ability

In vivo neutron capture therapy of cancer using ultrasmall gadolinium oxide nanoparticles with cancer-targeting ability

Insights into the Use of Gadolinium and Gadolinium/Boron-Based Agents in Imaging-Guided Neutron Capture Therapy Applications

Gadolinium delivery agents for neutron capture therapy

Contact Info

Product

Resources

About